Collaborators / Partners
AtomVie and Isotopia are collaborating to strengthen the global supply of the most commonly used radioisotope for targeted radiotherapy, lutetium-177 (Lu-177).
Since Lu-177 is more commonly used for radiotherapeutics, Isotopia has developed a new production technology for non-carrier added (n.c.a.) Lu-177 to ensure redundancy and shorter delivery times. To meet increasing supply demands in North America, this production technology has been successfully transferred into AtomVie’s current GMP facility. AtomVie started production of n.c.a. Lu-177 in April 2022 and has since achieved a stable and reliable supply.